# US 2014/0275278 A1 · Pharmaceutical composition of s-ketamine hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275278 A1
- Document ID: US20140275278A1
- Status: Published application
- Kind: A1
- Application number: 14/211,874
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: Esther D.G. Basstanie; Johanna Bentz; Roger C.A Embrechts; Nico Rudolph Niemeijer
- Web page: https://patentgrep.com/patent/US20140275278A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 9/0043: {Nose}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 47/02: Inorganic compounds
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 25/00: Drugs for disorders of the nervous system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.

## Claims

### Claim 1

A pharmaceutical composition comprising S-ketamine hydrochloride and water; wherein the pharmaceutical composition does not contain an antimicrobial preservative.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, which
(i) additionally contains a buffer; and/or
(ii) has a pH value within the range of from 4.0 to 6.5.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 100 mg/mL to eq. 200 mg/mL, based on the total volume of the composition.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 125 mg/mL to eq. 150 mg/mL, based on the total volume of the composition.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of 126 mg/mL to 162 mg/mL, based on the total volume of the composition.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated for nasal administration.

### Claim 7 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition further contains a buffer.

### Claim 8 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the buffer is 1N NaOH.

### Claim 9 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the buffer is present in an amount sufficient to adjust the pH of the pharmaceutical composition to a pH in the range of from pH 3.5 to pH 6.5.

### Claim 10 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the buffer is present in an amount sufficient to adjust the pH of the composition to a pH in the range of from pH 4.5 to pH 5.5.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition exhibits a shelf-life under accelerated storage conditions of at least 3 months.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1; wherein the pharmaceutical composition further contains a penetrating agent.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11; wherein the penetrating agent is tauroursodeoxycholic acid.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1; wherein the pharmaceutical composition further contains tauroursodeoxycholic acid in a concentration in the range of from 1 mg/mL to 25 mg/mL, based on the total volume of the composition.

### Claim 15 (depends on 2)

The pharmaceutical composition according to claim 2; wherein the pharmaceutical composition further contains tauroursodeoxycholic acid in a concentration in the range of from 5 mg/mL to 10 mg/mL.

### Claim 16 (depends on 1)

A pharmaceutical dosage form comprising the pharmaceutical composition according to any of claims 1.

### Claim 17 (depends on 15)

The dosage form according to claim 15, which is adapted for nasal administration.

### Claim 18 (depends on 1, 16)

The pharmaceutical composition according to claim 1 or the pharmaceutical dosage form according to claim 16 for use in the treatment of depression.

### Claim 19 (depends on 18)

The pharmaceutical composition or the pharmaceutical dosage form according to claim 18, wherein the depression is selected from the group consisting of major depressive disorder, unipolar depression, treatment-refractory depression, resistant depression, anxious depression and bipolar depression.

### Claim 20 (depends on 18)

The pharmaceutical composition or the pharmaceutical dosage form according to claim 18, wherein the depression is selected from the group consisting of resistant depression or treatment refractory depression.

### Claim 21

A pharmaceutical composition comprising S-ketamine hydrochloride as herein described.

### Claim 22

A dosage form comprising a pharmaceutical composition as herein described.

### Claim 23

A method of treating any disorder herein described comprising administration of a therapeutically effective amount of a pharmaceutical composition as herein described.
